Summary

Our study uses an extensive, iterative research technique with a deviation minimization focus to produce the most precise estimates and forecasts. The organization divides and estimates quantitative parts of the market using a mix of top-down and bottom-up methodologies. Additionally, data triangulation—which examines the market from three angles—recurs frequently in all of our research studies.

On many fronts, raw market data is gathered and compiled. To make sure that only verified and authenticated sources are taken into consideration, data is constantly vetted. Furthermore, data is extracted from numerous reports within our repository and several well-known commercial databases. Understanding the entire value chain is crucial for a thorough understanding of the market, and we gather information from buyers, distributors, and suppliers of raw materials to make this process easier.

Trade journals, technical symposia, and surveys are good sources for technical concerns and trends. Technical information is also obtained with an emphasis on white space and freedom of movement from an intellectual property standpoint. Additionally gathered are industry factors pertaining to pricing patterns, constraints, and drivers. This means that a variety of original data are included in the material that is produced, and this data is further cross-validated and certified with public sources.
We use simulation models to produce our market estimates and forecasts. A distinct model is built specifically for every investigation. Data is supplied into the model and simultaneously examined for pricing patterns, application development, market dynamics, and technology landscape. These parameters are compared, and time series analysis, regression, and correlation are used to quantify their impact across the predicted period. Market forecasting is carried out using a mix of technical analysis, industry experience, and domain knowledge in addition to economic instruments.

Technological market models are utilized for long-term forecasting, while econometric models are typically employed for short-term forecasting. These are grounded in a combination of corporate principles, regulatory frameworks, economic outlooks, and the state of technology.

Infection Control Market based on Type:
• Equipment
• Services
• Consumables
• Others
Infection Control Market based on End-use:
• Hospitals
• Medical Device Companies
• Clinical Laboratories
• Pharmaceutical Laboratories
• Others
Infection Control Market based on Geography:
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe (RoE)
• Asia Pacific (APAC)
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific (RoAPAC)
• Latin America (LATAM)
o Brazil
o Argentina
o Rest of South America
• Middle East and Africa (MEA)
o UAE
o Turkey
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
The significant portion is mostly due to the increased risk of contracting diseases on hospital property as a result of respiratory or bloodborne pathogen transmission. Since HAIs are one of the main problems, strict control is necessary. Hospitals and public health groups have been pushed to implement extremely effective control systems as a result. Additionally, it was anticipated that surgical sites accounted for 40% to 60% of hospital infections, according to studies published in NCBI.

The significant danger of infection from drug-resistant bacteria, bloodborne infections, and other pathogens in the operating room is one of the key concerns. For example, the frequent use of urinary catheters raises the risk of catheter-associated (CA) UTIs and UTIs overall. A study published in NCBI found that UTIs account for 25% of all bacterial illnesses. According to data from the National Nosocomial Infection Surveillance (NNIS) system report, the majority of hospital-acquired UTIs are associated with catheterization, and CA-bacteriuria is the most common HAI worldwide, accounting for up to 40% of HAIs in the United States annually. It is expected that these factors will boost the market's potential for future expansion.

The greater portion that this sector has taken is believed to be the result of numerous strategic alliances that major industry participants have embraced in order to increase the scope of their product offerings and infection control capacities. Furthermore, the reason North America has the largest market share in this region is because of the established companies' intensified attempts to develop their presence there.

The Asia Pacific market is expected to grow at the fastest rate throughout the course of the projection period due to the growing number of outsourcing businesses, rising healthcare spending, and substantial improvements in healthcare infrastructure.

In terms of region, the market share of infection control supplies in North America was 37.5% in 2022. One of the main forces for regional expansion is the rise in healthcare costs. Furthermore, the need for infection control products in North America has been further boosted by the rising incidence of infectious diseases as well as increased knowledge of personal hygiene and testing for urinary tract infections. Leading industry firms with a focus on product developments, such Cardinal Health, 3M, and others, are also located in the region, contributing to the expansion of the industry.

• This report illustrates the most vital attributes of the Infection Control Market, which are driving and providing opportunities.
• This research gives an in-depth analysis of the Infection Control Market growth on the basis of several segments in the market.
• This report presents the predictions of the past and present trends of the Infection Control Market.
• This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Infection Control Market.

ページTOPに戻る

Table of Contents

Table of Contents
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Type: Market Size & Analysis
5.1. Overview
5.2. Equipment
5.3. Services
5.4. Consumables
5.5. Others
6. End-use: Market Size & Analysis
6.1. Overview
6.2. Hospitals
6.3. Medical Device Companies
6.4. Clinical Laboratories
6.5. Pharmaceutical Laboratories
6.6. Others
7. Geography: Market Size & Analysis
7.1. Overview
7.2. North America (U.S., Mexico, Canada)
7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
7.5. Latin America (Brazil, Argentina)
7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
8. Competitive Landscape
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. Vendor Profiles
9.1. 3M COMPANY
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. BELIMED AG
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. HALYARD HEALTH, INC.
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. GETINGE GROUP
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. ADVANCED STERILIZATION PRODUCTS
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. MATCHANA GROUP
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. STERIGENICS INTERNATIONAL
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. MMM GROUP
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. CANTEL MEDICAL CORPORATION
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. STERIS CORPORATION
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
10. Analyst Opinion
11. Annexure
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1. INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 2. INFECTION CONTROL MARKET VALUE FOR EQUIPMENT, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. INFECTION CONTROL MARKET VALUE SERVICES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. INFECTION CONTROL MARKET VALUE FOR CONSUMABLES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. INFECTION CONTROL MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 7. INFECTION CONTROL MARKET VALUE FOR HOSPITALS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. INFECTION CONTROL MARKET VALUE FOR MEDICAL DEVICE COMPANIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. INFECTION CONTROL MARKET VALUE FOR CLINICAL LABORATORIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. INFECTION CONTROL MARKET VALUE FOR PHARMACEUTICAL LABORATORIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. NORTH AMERICA INFECTION CONTROL MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 14. U.S INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 15. U.S INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 16. CANADA INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 17. CANADA INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 18. MEXICO INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 19. MEXICO INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 20. EUROPE INFECTION CONTROL MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 21. EUROPE INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 22. EUROPE INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 23. GERMANY INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 24. GERMANY INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 25. U.K INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 26. U.K INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 27. FRANCE INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 28. FRANCE INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 29. ITALY INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 30. ITALY INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 31. SPAIN INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 32. SPAIN INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 33. ROE INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 34. ROE INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 35. ASIA PACIFIC INFECTION CONTROL MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 36. ASIA PACIFIC INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 37. ASIA PACIFIC INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 38. CHINA INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 39. CHINA INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 40. INDIA INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 41. INDIA INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 42. JAPAN INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 43. JAPAN INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 44. REST OF APAC INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 45. REST OF APAC INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 46. LATIN AMERICA INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 47. LATIN AMERICA INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 48. BRAZIL INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 49. BRAZIL INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 50. ARGENTINA INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 51. ARGENTINA INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 52. MIDDLE EAST AND AFRICA INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 53. MIDDLE EAST AND AFRICA INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 54. SAUDI ARABIA INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 55. SAUDI ARABIA INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 56. UAE INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 57. UAE INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 58. REST OF MIDDLE EAST AND AFRICA INFECTION CONTROL MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 59. REST OF MIDDLE EAST AND AFRICA INFECTION CONTROL MARKET VALUE, BY END USE, 2021-2030 (USD BILLION)
TABLE 60. 3M GROUP: FINANCIALS
TABLE 61. 3M GROUP: PRODUCTS & SERVICES
TABLE 62. 3M GROUP: RECENT DEVELOPMENTS
TABLE 63. BELIMED AG: FINANCIALS
TABLE 64. BELIMED AG: PRODUCTS & SERVICES
TABLE 65. BELIMED AG: RECENT DEVELOPMENTS
TABLE 66. HALYARD HEALTH, INC.: FINANCIALS
TABLE 67. HALYARD HEALTH, INC.: PRODUCTS & SERVICES
TABLE 68. HALYARD HEALTH, INC.: RECENT DEVELOPMENTS
TABLE 69. GETINGE GROUP: FINANCIALS
TABLE 70. GETINGE GROUP: PRODUCTS & SERVICES
TABLE 71. GETINGE GROUP: RECENT DEVELOPMENTS
TABLE 72. ADVANCED STERILIZATION PRODUCTS: FINANCIALS
TABLE 73. ADVANCED STERILIZATION PRODUCTS: PRODUCTS & SERVICES
TABLE 74. ADVANCED STERILIZATION PRODUCTS: RECENT DEVELOPMENTS
TABLE 75. MATCHANA GROUP: FINANCIALS
TABLE 76. MATCHANA GROUP: PRODUCTS & SERVICES
TABLE 77. MATCHANA GROUP: RECENT DEVELOPMENTS
TABLE 78. STERIGENICS INTERNATIONAL: FINANCIALS
TABLE 79. STERIGENICS INTERNATIONAL: PRODUCTS & SERVICES
TABLE 80. STERIGENICS INTERNATIONAL: DEVELOPMENTS
TABLE 81. MMM GROUP: FINANCIALS
TABLE 82. MMM GROUP: PRODUCTS & SERVICES
TABLE 83. MMM GROUP: RECENT DEVELOPMENTS
TABLE 84. CANTEL MEDICAL CORPORATION: FINANCIALS
TABLE 85. CANTEL MEDICAL CORPORATION: PRODUCTS & SERVICES
TABLE 86. CANTEL MEDICAL CORPORATION: RECENT DEVELOPMENTS
TABLE 87. STERIS CORPORATION: FINANCIALS
TABLE 88. STERIS CORPORATION: PRODUCTS & SERVICES
TABLE 89. STERIS CORPORATION: RECENT DEVELOPMENTS